Plasma β-amyloid in Alzheimer's disease and vascular disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer’s disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Correlations between plasma and CSF Aβ and between plasma Aβ and [18F]flutemetamol SUVR. (A–C) Plasma (Simoa immunoassay) and CSF (Euroimmun immunoassay) Aβ42 and Aβ40 were measured in a cohort of 719 individuals (174 SCI, 214 MCI, 57 AD patients and 274 controls). (D–F) Neuocortical amyloid deposition was measured using [18F]flutemetamol PET in a cohort of 340 individuals (103 SCI, 112 MCI patients and 125 controls). Correlation coefficients (r) and p-values are from Pearson’s correlation analysis. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; PET, positron emission tomography; SUVR, standardized uptake value ratio.](https://figures.cochat.ai/paper-figures/71bfab0f50314c6182d3ebedc2d5d0c6/plasma-amyloid-in-alzheimer-s-disease-and-vascular-disease-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a 65-year-old woman with only amyloid biomarkers but who is cognitively normal and has no neurodegeneration has a 10-year Alzheimer's disease risk of 2·5% and a man 2·3%, but the risk is higher with accompanying neurodegeneration (table 2 ).185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A model of lifetime risks of people who are amyloid positive without any other biomarkers finds it to be 8·4% for a 90-year-old woman who is cognitively normal at baseline, 23·5% for a 75-year-old woman and 29·3% for a 65-year-old woman.185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredIn the citing paper
“Although previous studies have found associations between CSF and PET Aβ and plasma Aβ using different immunoassays,7,12,13,14,44,45 the present Elecsys assays produced among the best accuracies and they are the first fully automated assays to have these greater accuracies.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationRissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationA New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L. O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Ader, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,797
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
The Microbleed Anatomical Rating Scale (MARS): Reliability of a tool to map brain microbleeds
Gregoire, S. M., Chaudhary, U. J., Brown, M. M., Yousry, T. A., Kallis, C., Jäger, H. R., & Werring, D. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34a7d · Cited by 846
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Self-citationPlasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458
CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Self-citationClinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Self-citationGraff-Radford, N. R., Crook, J. E., Lucas, J., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 441
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. M., Patton, R. L., Luehrs, D. C., Daugs, I. D., Kuo, Y., et al. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.10.004 · Cited by 414
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375
Self-citationPalmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368
Self-citationPlasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy
Gurol, M. E., Irizarry, M. C., Smith, E. E., Raju, S., Diaz-Arrastia, R., Bottiglieri, T., Rosand, J., Growdon, J. H., & Greenberg, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000191403.95453.6a · Cited by 339
APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Michaelson, D. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.015 · Cited by 331
Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andreasson, U., Londos, E., Wallin, A., Minthon, L., & Blennow, K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.027 · Cited by 281
Self-citationPeripheral Aβ subspecies as risk biomarkers of Alzheimer's disease
Schupf, N., Tang, M. X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., Ravetch, J., & Mayeux, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805902105 · Cited by 225
Koole, M., Lewis, D. M., Buckley, C., Nelissen, N., Vandenbulcke, M., Brooks, D. J., Vandenberghe, R., & Van Laere, K. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060756 · Cited by 212
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., Decarli, C., Toga, A. W., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0861-8 · Cited by 177
Developing novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
Self-citationHypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans
Zetterberg, H., Mörtberg, E., Song, L., Chang, L., Provuncher, G. K., Patel, P. P., Ferrell, E., Fournier, D. R., Kan, C. W., Campbell, T. G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028263 · Cited by 173
Self-citationChanges in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 142
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Self-citationStamatelopoulos, K. S., Sibbing, D., Rallidis, L. S., Georgiopoulos, G. A., Stakos, D., Braun, S., Gatsiou, A., Sopova, K., Kotakos, C., Varounis, C., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.035 · Cited by 134
Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions
van Dijk, E. J., Prins, N. D., Vermeer, S. E., Albert Hofman, D., van Duijn, C. M., Koudstaal, P. J., & Breteler, M. M. B. (2004) · Annals of Neurology · doi:10.1002/ana.20050 · Cited by 133
Paris, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F., & Mullan, M. (2003) · Neurological Research · doi:10.1179/016164103101201940 · Cited by 127
Lautner, R., Palmqvist, S., Mattsson, N., Andréasson, U., Wallin, A., Pålsson, E., Jakobsson, J., Herukka, S., Owenius, R., Olsson, B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1060 · Cited by 126
Self-citationBurnham, S. C., Faux, N. G., Wilson, W. J., Laws, S. M., Ames, D. J., Bedő, J., Bush, A. I., Doecke, J. D., Ellis, K. A., Head, R. J., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.40 · Cited by 125
Lundqvist, R., Lilja, J., Thomas, B. A., Lötjönen, J. M. P., Villemagne, V. L., Rowe, C. C., & Thurfjell, L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.115006 · Cited by 117
Lewczuk, P., Kornhuber, J., Vanmechelen, E., Peters, O., Heuser, I., Maier, W., Jessen, F., Bürger, K., Hampel, H. J., Frölich, L., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.024 · Cited by 115
Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment
Pesaresi, M., Lovati, C., Bertora, P., Mailland, E., Galimberti, D., Scarpini, E. A., Quadri, P., Forloni, G., & Mariani, C. B. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.004 · Cited by 111
Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion
Bennett, S. A. L., Pappas, B. A., Stevens, W. D., Davidson, C. M., Fortin, T., & Chen, J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00131-7 · Cited by 110
Association of Plasma Aß Peptides with Blood Pressure in the Elderly
Lambert, J., Dallongeville, J., Ellis, K. A., Schraen‐Maschke, S., Lui, J. K., Laws, S. M., Dumont, J., Richard, F., Cottel, D., Berr, C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018536 · Cited by 81
Hansson, O., Stomrud, E., Vanmechelen, E., Östling, S., Gustafson, D., Zetterberg, H., Blennow, K., & Skoog, I. G. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111418 · Cited by 57
Self-citationPlasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke
Hernández‐Guillamón, M., Delgado, P., Peñalba, A., Rodríguez‐Luna, D., Molina, C. A., Rovira, À., Álvarez‐Sabín, J., Boada, M., & Montaner, J. (2012) · Neurodegenerative Diseases · doi:10.1159/000333811 · Cited by 53
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
Swaminathan, S., Risacher, S. L., Yoder, K. K., West, J. D., Shen, L., Kim, S., Inlow, M. H., Foroud, T., Jagust, W., Koeppe, R. A., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.007 · Cited by 49
Bornebroek, M., Jonghe, C. D., Haan, J., Kumar‐Singh, S., Younkin, S., Roos, R. A. C., & Broeckhoven, C. V. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.019 · Cited by 44
Plasma β‐Amyloid Peptide, Transforming Growth Factor‐β1, and Risk for Cerebral Amyloid Angiopathy
Greenberg, S. M., CHO, H., O’Donnell, H. C., Rosand, J. M., Segal, A. Z., Younkin, L. H., Younkin, S. G., & Rebeck, G. W. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06361.x · Cited by 42
Performance Characteristics of Plasma Amyloid-β 40 and 42 Assays
Okereke, O. I., Xia, W., Irizarry, M. C., Sun, X., Qiu, W. Q., Fagan, A. M., Mehta, P. D., Hyman, B. T., Selkoe, D. J., & Grodstein, F. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0948 · Cited by 40
Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments
Lista, S., Zetterberg, H., Dubois, B., Blennow, K., & Hampel, H. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7366-z · Cited by 40
Self-citationLachno, D. R., Emerson, J. K., Vanderstichele, H., Gonzales, C., Martényi, F., Konrad, R. J., Talbot, J. A., Lowe, S. L., Oefinger, P. E., & Dean, R. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121075 · Cited by 35
Research works printed but not linked: 1
- Janelidze, S. et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology (In press).
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
“These results are similar to other amyloid blood biomarkers 189,190 and harmonisation to a common reference standard is now vital.”
RetractedScheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citation
Metadata
- Authors
- Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- National Hospital for Neurology and Neurosurgery (GB)
- Quanterix (United States) (US)
- University of Gothenburg (SE)
- Corresponding author
- Janelidze, Shorena
- Hansson, Oskar
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-05-31
- Volume
- 6
- Issue
- 1
- Pages
- 26801-26801
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4886210
- OpenAlex
- W2414917913
- Cited by
- 626
- References
- 49
- Citations by year
- 2026: 53 · 2025: 59 · 2024: 75 · 2023: 77 · 2022: 80 · 2021: 75 · 2020: 73 · 2019: 59 · 2018: 45 · 2017: 22 · 2016: 6
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Crafoordska Stiftelsen
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- plasma amyloid-beta, amyloid-beta 42, Aβ40, Alzheimer's disease, vascular disease, amyloid biomarkers, cerebrospinal fluid, white matter lesions, cerebral microbleeds, hypertension, diabetes mellitus, ischemic heart disease, mild cognitive impairment, subjective cognitive decline, amyloid PET, amyloid metabolism
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Male, Vascular Diseases, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Neocortex, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.